| scholarly article | Q13442814 |
| P50 | author | Claudine S. Bonder | Q91341775 |
| Lisa M Ebert | Q57415932 | ||
| P2093 | author name string | Michael P Brown | |
| Zvi G Fridlender | |||
| Carmela Martini | |||
| Lih Yin Tan | |||
| P2860 | cites work | Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice | Q83427822 |
| Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma | Q84405957 | ||
| Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells | Q84470745 | ||
| Integrin alphaDbeta2, an adhesion receptor up-regulated on macrophage foam cells, exhibits multiligand-binding properties | Q24538851 | ||
| Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy | Q24596055 | ||
| Platelets Guide Leukocytes to Their Sites of Extravasation | Q27342832 | ||
| Immune checkpoint blockade: a common denominator approach to cancer therapy | Q28083981 | ||
| Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade | Q28119095 | ||
| Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense | Q28186087 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN | Q29619346 | ||
| Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. | Q30358552 | ||
| Vascular channels formed by subpopulations of PECAM1+ melanoma cells | Q30413784 | ||
| Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment | Q30415355 | ||
| CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease | Q30435000 | ||
| A novel function of junctional adhesion molecule-C in mediating melanoma cell metastasis. | Q30501230 | ||
| Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays | Q33665758 | ||
| Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors | Q33765767 | ||
| Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade | Q33898182 | ||
| BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice | Q33996674 | ||
| Platelets guide the formation of early metastatic niches | Q34002250 | ||
| Adoptive cell transfer as personalized immunotherapy for human cancer | Q34043643 | ||
| Leukocyte recruitment at sites of tumor: dissonant orchestration | Q34330220 | ||
| Neoantigens in cancer immunotherapy. | Q34470074 | ||
| The role of chemokines in melanoma tumor growth and metastasis | Q34680888 | ||
| CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice | Q35015717 | ||
| Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies | Q35088257 | ||
| Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. | Q35237477 | ||
| BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth | Q35251663 | ||
| Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer | Q35463514 | ||
| Induction of Vasculogenic Mimicry Overrides VEGF-A Silencing and Enriches Stem-like Cancer Cells in Melanoma | Q35463820 | ||
| Tumor angiogenesis induced by granulocyte chemotactic protein-2 as a countercurrent principle | Q35746831 | ||
| Melanoma-associated expression of transforming growth factor-beta isoforms | Q35773976 | ||
| Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment | Q35783465 | ||
| CANCER IMMUNOLOGY. The "cancer immunogram". | Q36010386 | ||
| Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints | Q36160526 | ||
| Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses | Q36333963 | ||
| Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma | Q36364471 | ||
| Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model | Q36615128 | ||
| Dynamic Patterns of Clonal Evolution in Tumor Vasculature Underlie Alterations in Lymphocyte-Endothelial Recognition to Foster Tumor Immune Escape | Q36693233 | ||
| Using macrophage activation to augment immunotherapy of established tumours | Q36747346 | ||
| Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy | Q37087603 | ||
| Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma | Q37178677 | ||
| CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. | Q37279217 | ||
| Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model | Q37650141 | ||
| Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance? | Q37846342 | ||
| Tumor-associated macrophages: functional diversity, clinical significance, and open questions | Q38105286 | ||
| Regulatory T cells in cancer immunotherapy | Q38177627 | ||
| How leukocytes cross the vascular endothelium | Q38608338 | ||
| Tumor cell vascular mimicry: Novel targeting opportunity in melanoma | Q38710798 | ||
| GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade | Q38782845 | ||
| Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? | Q38845962 | ||
| BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro | Q38938635 | ||
| Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression | Q39087629 | ||
| Vemurafenib reverses immunosuppression by myeloid derived suppressor cells | Q39445924 | ||
| A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice | Q39666028 | ||
| Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. | Q40031362 | ||
| Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft | Q40140782 | ||
| Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A. | Q40369844 | ||
| High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. | Q40569572 | ||
| Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease. | Q40864107 | ||
| Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment | Q41150808 | ||
| Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab | Q41469907 | ||
| VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma | Q41636554 | ||
| Endothelial P-selectin expression is reduced in advanced primary melanoma and melanoma metastasis. | Q41971783 | ||
| Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma | Q42482085 | ||
| Integrin CD11c/CD18 α-chain phosphorylation is functionally important. | Q42905780 | ||
| Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. | Q43665853 | ||
| Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab | Q44017442 | ||
| Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression | Q45201798 | ||
| Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy | Q46817579 | ||
| Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma | Q47573472 | ||
| L1 adhesion molecule on human lymphocytes and monocytes: expression and involvement in binding to alpha v beta 3 integrin | Q48059490 | ||
| Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study | Q48401064 | ||
| Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. | Q50505009 | ||
| VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation. | Q50848908 | ||
| Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. | Q50996147 | ||
| Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. | Q52832336 | ||
| Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: a meta-analysis. | Q53168767 | ||
| Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. | Q53281128 | ||
| Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. | Q53391760 | ||
| Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. | Q54133911 | ||
| CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-β. | Q54704650 | ||
| An immune-active tumor microenvironment favors clinical response to ipilimumab | Q56898024 | ||
| Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer | Q58212139 | ||
| A study of adhesion molecules as markers of progression in malignant melanoma | Q58212505 | ||
| Epigenetic Regulation of Tumor Endothelial Cell Anergy: Silencing of Intercellular Adhesion Molecule-1 by Histone Modifications | Q60541942 | ||
| Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8 | Q61609536 | ||
| Low-Level Monocyte Chemoattractant Protein-1 Stimulation of Monocytes Leads to Tumor Formation in Nontumorigenic Melanoma Cells | Q61609539 | ||
| A chemokine receptor antagonist inhibits experimental breast tumor growth | Q61819228 | ||
| Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis | Q72559262 | ||
| Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression | Q73344300 | ||
| T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma | Q75402946 | ||
| T-cell distribution and adhesion receptor expression in metastatic melanoma | Q80249359 | ||
| Role of galectin-3 in leukocyte recruitment in a murine model of lung infection by Streptococcus pneumoniae | Q80633633 | ||
| The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase | Q81000005 | ||
| Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma | Q81393637 | ||
| Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma | Q82174987 | ||
| Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth | Q83427428 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | e134 | |
| P577 | publication date | 2017-03-17 | |
| P1433 | published in | Clinical & translational immunology | Q27725955 |
| P1476 | title | Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy? | |
| P478 | volume | 6 |
| Q60938431 | A Computational Approach Identifies Immunogenic Features of Prognosis in Human Cancers |
| Q93270141 | Effects of anti-PD-1 immunotherapy on tumor regression: insights from a patient-derived xenograft model |
| Q91779668 | Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga |
| Q51765579 | Molecular Magnetic Resonance Imaging of Endothelial Activation in the Central Nervous System. |
| Q58607867 | Nondestructive, multiplex three-dimensional mapping of immune infiltrates in core needle biopsy |
| Q49166013 | Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer |
| Q41935730 | Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination |
| Q55343888 | Transcriptome-derived stromal and immune scores infer clinical outcomes of patients with cancer. |
| Q92855987 | Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope? |
Search more.